Bacteriophages of Pseudomonas aeruginosa: Long-Term Prospects for Use in Phage Therapy

被引:31
作者
Krylov, Victor N. [1 ]
机构
[1] Russian Acad Med Sci, Mechnikov Res Inst Vaccines & Sera, Moscow, Russia
来源
ADVANCES IN VIRUS RESEARCH, VOL 88 | 2014年 / 88卷
关键词
CYSTIC-FIBROSIS PATIENTS; BURKHOLDERIA-CEPACIA COMPLEX; COMPLETE GENOME SEQUENCE; MU-LIKE BACTERIOPHAGES; ESCHERICHIA-COLI; TRANSPOSABLE PHAGES; PHI-KZ; INNER BODY; EPIDEMIC STRAIN; GENETIC-CONTROL;
D O I
10.1016/B978-0-12-800098-4.00005-2
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bacteria Pseudomonas aeruginosa, being opportunistic pathogens, are the major cause of nosocomial infections and, in some cases, the primary cause of death. They are virtually untreatable with currently known antibiotics. Phage therapy is considered as one of the possible approaches to the treatment of P. aeruginosa infections. Difficulties in the implementation of phage therapy in medical practice are related, for example, to the insufficient number and diversity of virulent phages that are active against P. aeruginosa. Results of interaction of therapeutic phages with bacteria in different conditions and environments are studied insufficiently. A little is known about possible interactions of therapeutic phages with resident prophages and plasmids in clinical strains in the foci of infections. This chapter highlights the different approaches to solving these problems and possible ways to expand the diversity of therapeutic P. aeruginosa phages and organizational arrangements (as banks of phages) to ensure long-term use of phages in the treatment of P. aeruginosa infections.
引用
收藏
页码:227 / 278
页数:52
相关论文
共 174 条
  • [51] In vitro lung delivery of bacteriophages KS4-M and ΘKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis
    Golshahi, L.
    Lynch, K. H.
    Dennis, J. J.
    Finlay, W. H.
    [J]. JOURNAL OF APPLIED MICROBIOLOGY, 2011, 110 (01) : 106 - 117
  • [52] GORBUNOVA SA, 1985, GENETIKA+, V21, P1455
  • [53] Genomic sequence and activity of KS10, a transposable phage of the Burkholderia cepacia complex
    Goudie, Amanda D.
    Lynch, Karlene H.
    Seed, Kimberley D.
    Stothard, Paul
    Shrivastava, Savita
    Wishart, David S.
    Dennis, Jonathan J.
    [J]. BMC GENOMICS, 2008, 9 (1)
  • [54] Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage
    Hagens, S
    Habel, A
    von Ahsen, U
    von Gabain, A
    Bläsi, U
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) : 3817 - 3822
  • [55] Genetically modified filamentous phage as bactericidal agents:: a pilot study
    Hagens, S
    Bläsi, U
    [J]. LETTERS IN APPLIED MICROBIOLOGY, 2003, 37 (04) : 318 - 323
  • [56] Microbial ecology of the cystic fibrosis lung
    Harrison, Freya
    [J]. MICROBIOLOGY-SGM, 2007, 153 : 917 - 923
  • [57] New temperate DNA phage BcP15 acts as a drug resistance vector
    Hens, D. K.
    Chatterjee, N. C.
    Kumar, R.
    [J]. ARCHIVES OF VIROLOGY, 2006, 151 (07) : 1345 - 1353
  • [58] Genome sequence comparison and superinfection between two related Pseudomonas aeruginosa phages, D3112 and MP22
    Heo, Yun-Jeong
    Chung, In-Young
    Choi, Kelly B.
    Lau, Gee W.
    Cho, You-Hee
    [J]. MICROBIOLOGY-SGM, 2007, 153 : 2885 - 2895
  • [59] Genome comparison of Pseudomonas aeruginosa large phages
    Hertveldt, K
    Lavigne, R
    Pleteneva, E
    Sernova, N
    Kurochkina, L
    Korchevskii, R
    Robben, J
    Mesyanzhinov, V
    Krylov, VN
    Volckaert, G
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2005, 354 (03) : 536 - 545
  • [60] HOLLOWAY B. W., 1960, AUSTRALIAN JOUR EXPTL BIOL AND MED SCI, V38, P321, DOI 10.1038/icb.1960.34